Navigation Links
Helix BioPharma Corp. Announces Fiscal 2009 Results
Date:10/29/2009

Product revenue in fiscal 2009 totalled $3,244,000 and represents an increase of $292,000 or 9.9% when compared to product revenue in fiscal 2008 of $2,952,000. Product sales of Orthovisc® grew in fiscal 2009 while Klean-Prep(TM) revenue remained relatively stable. License fees and royalties in fiscal 2009 totalled $597,000 and represent a decrease of $42,000 or 6.6% when compared to fiscal 2008. The decrease reflects lower Klean-Prep(TM) royalty revenue from Helsinn-Birex which was offset by the final payment from Lumera Corporation of US$75,000 when it provided the Company with notice of termination of its sub-license agreement.

Cost of sales in fiscal 2009 and 2008 totalled $1,516,000 and $1,239,000, respectively. As a percentage of product revenues, cost of sales in fiscal 2009 and 2008 were 46.7% and 42.0%, respectively. In addition to some foreign exchange impact, cost of sales was also impacted by higher distribution costs. The increase in cost of sales, on a percentage, basis was mainly the result of lower average selling price per units sold of Orthovisc®. Lower pricing was offered on Orthovisc® to assist in customer retention for a scheduled launch of a new, single injection product in the first quarter of fiscal 2010.

Research and development expenditures in fiscal 2009 totalled $10,322,000 and represent an increase of $5,258,000 or 103.8% when compared to fiscal 2008. L-DOS47 and Topical Interferon Alpha-2b reflect an increase of 52.6% and 171.2%, respectively. The increase in research and development expenditures associated with L-DOS47, are primarily related to the scale-up manufacturing program and ongoing collaborative research initiatives in anticipation of furnishing product for future clinical testing. The increase in research and development expenditures associated with Topical Interferon Alpha-2b reflect the ongoing costs for the AGW Phase II clinical trial in Sweden and Germany in addition to scale-u
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
4. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
7. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
8. PDL BioPharma Completes October 1 Special Dividend Payment
9. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... DUBLIN , Apr. 17, 2015 Research ... announced the addition of the "Medical Device ... to their offering. This report analyzes ... US$ Million by the following Device Categories: Class ... areas also analyzed in the report Include - ...
(Date:4/17/2015)... 17, 2015  Trovagene, Inc., (NASDAQ:  TROV) a ... clinical data presented at the 2015 European Lung ... Cancer Monitoring ℠ (PCM) platform outperformed tissue ... EGFR T790M mutations in metastatic lung cancer ... T790M Mutation in Urinary Circulating Tumor DNA from ...
(Date:4/17/2015)... 2015 Steven Rash , the CEO of ... operating subsidiary American Seed & Oil Company, presented the ... yesterday in New York City.  Mr. Rash,s presentation featured ... Seed & Oil Company has recently announced the ... Seed Foods , the EpiVape , and ...
Breaking Medicine Technology:Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3
... Silence Therapeutics plc (AIM: SLN) ("Silence" or ... patent 7,893,245, titled "Interfering RNA Molecules," by the ... issued patent, which represents a continuation of previously ... RNAi molecules with defined positional modifications including siRNA ...
... Feb. 22, 2011 Covance Inc. (NYSE: CVD ... Annual Morningstar/NYSSA Healthcare Conference on Thursday, February 24, 2011 at ... the presentation at www.covance.com .  In order to register ... early. Covance, with headquarters in Princeton, New Jersey, ...
Cached Medicine Technology:Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 2Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 3Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 4Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference 2
(Date:4/17/2015)... 17, 2015 Wholelifelifeinsurance.org has released ... whole life insurance policies . , Whole ... financial security for their families at the same time. ... options which can be customized to it the client’s ... reduced if clients take some appropriate steps.Comparing life insurance ...
(Date:4/17/2015)... Verndale, a Global Experience Technology Company, is pleased ... as a Boston Business Journal (BBJ) Pacesetter, ranking as ... The BBJ’s Pacesetters represents privately held businesses that recorded ... is the eighth consecutive year and the ninth time ... honored with this award. , “Being honored with this ...
(Date:4/17/2015)... 17, 2015 Cheapquotesautoinsurance.com has released a new ... has a salvage title . , An auto insurance ... a salvage title if the owner has paid for all ... title car is not possible, while in other states, the ... blog post provides more information on the subject. , ...
(Date:4/17/2015)... 17, 2015 Founder of the ... as a keynote speaker at the Couples Conference from ... Marriott in Manhattan Beach, CA. Tatkin’s presentation and panel ... can help couples become “secure-functioning” – a term he ... of research in neurobiology, arousal regulation, and infant attachment ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 The American ... that Long Island eye surgeon Jeffrey L. Martin, will ... Cataract Surgery Skills Transfer Session being held April 17-21 ... Martin is the Managing Partner of North Shore Eye ... fellow ophthalmologists attending the Skills Transfer Session in learning ...
Breaking Medicine News(10 mins):Health News:Whole Life Insurance Policies At Affordable Prices By Comparing Quotes 2Health News:Verndale Honored as 2015 Boston Business Journal Pacesetter, Named 46th Fastest Growing Private Company 2Health News:Compare Auto Insurance Quotes for Cars With A Salvage Title! 2Health News:Best-Selling Author, Therapist and Founder of the PACT Institute Will Give a Keynote Address at 2015 Couples Conference 2Health News:Best-Selling Author, Therapist and Founder of the PACT Institute Will Give a Keynote Address at 2015 Couples Conference 3Health News:American Society of Cataract & Refractive Surgery Selects Dr. Jeffrey Martin To Serve As Lead Instructor For Laser Cataract Surgery Skills Transfer Session 2Health News:American Society of Cataract & Refractive Surgery Selects Dr. Jeffrey Martin To Serve As Lead Instructor For Laser Cataract Surgery Skills Transfer Session 3
... important regulatory enzyme may slow the loss of brain ... disorders. In a report receiving advance online publication ... (MGH)-based research team reports that increased expression of Sirt1, ... the brain of a mouse model of HD protected ...
... a dentist but not a general healthcare provider, according to an ... Health . The study, conducted by a nursing-dental research team ... proportion of Americans who are seen annually by a dentist but ... suggests dentists can play a crucial role as health care practitioners ...
... Reporter , FRIDAY, Dec. 16 (HealthDay News) -- Not only does ... in their quality of life, new research finds. ... are a lot of benefits that you might not have thought ... you,d have more stress, that quitting would put more stress on ...
... for the treatment of breast cancer has been ... the U.S. as an alternative to standard whole-breast ... 16th in the Journal of the ... APBI recurrence (external beam radiation, intraoperative radiotherapy, brachytherapy ...
... , FRIDAY, Dec. 16 (HealthDay News) -- First responders ... than double the rate of the general U.S. population, new ... 8 in the American Journal of Industrial Medicine , ... the result of their exposure to the toxic dust created ...
... Road Rippers Lightning Rods, Let,s Rock Elmo and the I ... season, parents should ensure that their children don,t risk permanent ... Department of Otolaryngology measured the noise levels of two dozen ... precise gauging in a soundproof booth at UC Irvine Medical ...
Cached Medicine News:Health News:Regulatory enzyme overexpression may protect against neurodegeneration in Huntington's disease 2Health News:NYU study concludes that dentists could screen 20 million Americans for chronic physical illnesses 2Health News:Life After Cigarettes Is Happier: Study 2Health News:Life After Cigarettes Is Happier: Study 3Health News:Advantages and motivations uncertain behind use of brachytherapy for breast cancer radiotherapy 2Health News:Advantages and motivations uncertain behind use of brachytherapy for breast cancer radiotherapy 3Health News:WTC First Responders More Likely to Have Asthma: Study 2Health News:UC Irvine researchers urge caution when buying noisy toys 2
Total IgE Control...
The K-ASSAY Lp(a) Control Set is intended for use as an assayed quality control material for monitoring the performance of Lp(a) immunoturbidimetric assays....
... The K-ASSAY ASO / ... is intended to be used ... of known concentration for monitoring ... O (ASO), Rheumatoid Factor (RF), ...
Eppendorf expands its line of benchtop microcentrifuges with the 5418. This easy-to-use microcentrifuge features a certified aerosol-tight rotor and a unique, contoured rotor bowl design to reduce no...
Medicine Products: